

Contents

Volume 1

Preface	xxvii
Executive Summary	xxxi

Part One: New Reproductive Technologies and Canadian Society

1	A Comprehensive Response to Issues of National Importance	1
	The Appointment of a Royal Commission	1
	The Commission's Mandate	2
	The Technologies	4
	Broader Questions	7
	Organization of the Commission's Work	7
	Overall Results of Our Inquiry	10
	The Call for National Action	11
	Is a Moratorium the Appropriate Response?	14
	A Matter of National Concern	15
	Comprehensive Policies and Regulation	
	Are Required	16
	Peace, Order, and Good Government	19
2	Social Values and Attitudes Toward Technology and New Reproductive Technologies	23
	Technology and Society	24
	Globalization	27
	Equality	28
	Pluralism and Diversity	29
	Empowerment	30
	Medicalization	32
	Impact of New Reproductive Technologies on Canadian Society	34
	Impact on Women	35
	Impact on Children	41
	Impact on Family Structure	42
	Impact on People with Disabilities	44
	Impact on Society	45
	A New Approach to Decisions About Technology	47

3	What Guided Our Deliberations: Ethical Framework and Guiding Principles	49
	The Ethic of Care and the Guiding Principles Approach	51
	The Ethic of Care	52
	The Guiding Principles	52
	What We Heard: Support for This Approach	58
	Applying the Guiding Principles	59
	Individual and Collective Interests	60
	Defining the Problem	60
	The Role of the Charter	61
	Situations Where Individual and Collective Interests May Differ	63
	Conclusion	65
4	New Reproductive Technologies and the Health Care System	69
	Evidence-Based Medicine	70
	Health Care and Health	73
	Pressures on the Health Care System	75
	Growing Use and Costs	76
	Government Expenditures on Health Care	78
	The Limits of the System	82
	The System's Limits and New Reproductive Technologies: The Issues of Access	84
	Emerging Issues in Health Care	86
	Quality Control	87
	Acute Care and Prevention	92
	The Role of the Patient: Informed Choice	93
	Privacy and Confidentiality	96
	New Reproductive Technologies and the Health Care System	99
5	Achieving Responsible Regulation of New Reproductive Technologies	107
	Federal Legislation: Establishing Boundaries and Setting Limits	108
	Calls for a National Reproductive Technologies Commission	110
	The Need for a National Regulatory Commission	111

Functions of the National Regulatory Commission	115
Licensing and Monitoring	116
Guideline and Standard Setting	117
Information Collection, Evaluation, and Dissemination	118
Records Storage	119
Consultation, Coordination, and Intergovernmental Cooperation	119
Monitoring of Future Technologies and Practices	121
Composition of the National Regulatory Commission	122
Other Federal Policy and Program Initiatives	123
Ensuring That Future Development Is in the Public Interest	124

Part Two: New Reproductive Technologies: Examination of Conditions, Technologies, and Practices



Developing a Comprehensive Picture of Technologies and Practices	129
Framework of Our Approach	129
Origins and Historical Development	131
Current Practices	131
Results and Outcomes	131
Costs and Benefits	132
Future Directions	132
Implications	132
Alternatives	133
Options Considered	134
Recommendations Made	134
Organization of the Commission's Work	135
Consultations and Communications	135
Research and Evaluation	137
New Reproductive Technologies Inquiries Elsewhere	139
Emerging Consensus, Continuing Disagreement, and Unresolved Issues	140

7	The Biology of Human Reproduction and Early Development	145
	Egg Production	146
	Sperm Production	147
	Fertilization	149
	The First 14 Days	149
	The Zygote and Its Genome	153
	Cleavage and the Blastomeres	155
	Implantation and Differentiation	155
	Failure of Zygotes to Develop	159
	Conclusion	159
8	Infertility: Prevalence, Risk Factors, and Prevention — Introduction	163
	The Social Context of Infertility	169
	The Social Meaning of a Biological Process	170
	The Underlying Causes of Infertility	175
9	Prevalence of Infertility	179
	Commission Research	181
	How We Defined and Measured Infertility for the Population Surveys	181
	Methodology	186
	Results	187
	Comparison of Canadian and U.S. Infertility Estimates	189
	Prevalence of Infertility by Region, Age Group, and Childbearing Status	190
	Secondary Research	191
	Trends in Infertility	192
	Implications of Prevalence Findings	194
	Appendix 1: The Prevalence of Infertility in Canada — Surveys Conducted for the Commission	194
	Appendix 2: One-Year and Two-Year Calculations of the Infertility Rate	195

10

Sexually Transmitted Diseases and Infertility 199

The Focus of Our Investigations	200
The Incidence of Sexually Transmitted Diseases	201
Gonorrhoeal Infections	202
Chlamydial Infections	205
Factors That Increase the Risk of Acquiring a STD	207
Sexually Transmitted Diseases and Infertility in Women	209
STDs and Pelvic Inflammatory Disease	209
Pelvic Inflammatory Disease and Tubal Infertility	211
Pelvic Inflammatory Disease and Ectopic Pregnancy	212
STDs and Adverse Pregnancy and Birth Outcomes	213
Sexually Transmitted Diseases and Male Fertility	214
Preventing Sexually Transmitted Diseases	214
Sexual Health Education	216
Health Care Professionals and the Prevention, Diagnosis, and Treatment of STDs	223
Research Needs	228
Preventing STD-Related Infertility: A Comprehensive Reproductive Health Strategy	229

11

Smoking and Infertility 235

Impact of Female Smoking on Fertility	236
Infertility Treatment Results and Smoking	237
Smoking, Pregnancy, and Birth Outcomes	238
Smoking and Age at Menopause	238
Male Smoking and Infertility	239
Preventing Reproductive Harm	240
Reducing and Preventing Tobacco Consumption	241
Reducing and Preventing Smoking Among Couples Who Plan to Become Pregnant	244
Preventing Smoking-Related Infertility	246

12

Age and Infertility 249

The Social Context of Age and Infertility	250
Demographic Trends in Childbearing	252
The Impact of Age on Female Fertility	255
Conception	256
Pregnancy and Birth Outcomes	260

The Impact of Age on Male Fertility	261
Implications	262
Preventing Age-Related Infertility	263

13 **Exposure to Harmful Agents in the Workplace and the Environment and Infertility** 269

Why So Little Is Known	270
Exposure to Harmful Agents in the Workplace	273
Current Knowledge	275
Preventing Reproductive Harm	279
The Environment and Reproductive Health	289
Current Knowledge	289
Current Legislative Framework	294
Proposed Action on Environmental Exposures	295
A Comprehensive Research Strategy	296

14 **Other Risk Factors and Infertility** 303

Eating Disorders, Weight, and Exercise	304
Undernutrition and Eating Disorders	304
Excessive Exercise	307
Endometriosis	309
Substance Use and Abuse	312
Alcohol	312
Illicit Drugs	316
Caffeine	320
Stress and Psychological Factors	320
Medical Intervention and Infertility	322
Method of Contraception	322
Surgical Procedures in Women	330
Surgical Procedures in Men	332
Radiation Therapy	332
Diagnostic Testing Procedures for Infertility	332
Prescription Drugs	334

15 **Preventing Infertility** 339

The Role of Prevention	343
Obstacles to Shifting Resources to Prevention Programs	346
Building on Success	350
A Comprehensive Response	353
Conclusion	356

16

Adoption**359**

Trends in Adoption in Canada	361
Canada's Adoption System	365
Public Adoption	366
Private Adoption	366
International Adoption	368
Custom Adoption	368
Access to Adoption	369
An Adoption System in the Best Interests of Children	371

17

Infertility Treatments: Introduction and Social Context**375**

The Social Context for Infertility Treatments: What We Heard	378
How Society Views Technology	379
Women's Reproductive Health and Well-Being	380
Decision Making About Infertility Treatments	382
Need for Informed Choice	382
Funding for Infertility Treatments	383
Access	384
Impact on the Family and Its Biological Relationships	385

18

Infertility Treatments: Fertility Drugs**387**

The Views of Canadians	388
The Development of Fertility Drugs	391
Effectiveness and Risks of Fertility Drugs	393
Ovulation Induction Drugs	394
Risks of Ovulation Induction	397
Ovulation Suppression Drugs	400
Drugs to Treat Male Infertility	401
Ensuring Safe and Effective Fertility Drug	
Treatment in the Future	402
The Drug Regulatory System	403
The Current System	404
Changes in the Drug Approval System	405
Recombinant Fertility Drugs	407
Ethical Review of Trials	408

Current Treatment and Prescription Practices	408
Prescription Practices	409
Informed Consent	411
Identifying Short-Term Effects	412
Tracking Long-Term Outcomes	416
Conclusion	419



Infertility Treatments: Assisted Insemination 425

The Views of Canadians	426
History and Development of Assisted Insemination	431
AI in Canada: Current Practice	434
Effectiveness of AI	438
Effectiveness of AIH	438
Risks and Effectiveness of Intrauterine Insemination and Related Techniques	439
Risks and Effectiveness of Donor Insemination	440
Issues in Sperm Donation, Collection, and Storage	441
Donor Anonymity	441
Informed Consent to Sperm Donation	446
Commercialization	447
Safety Issues	448
Other Uses for Sperm Banking Facilities	450
Issues in the Practice of Insemination	451
Medicalization	451
Access to Treatment	454
Alternatives to the Medical Setting	458
Information, Counselling, and Consent	460
Familial and Societal Implications of DI	463
Secrecy in DI Families	464
Legal Status of DI Families	465
Lessons from the Adoption Context	468
Recommendations	471
Licensing Requirements for Sperm Collection, Storage and Distribution, and Use	474
The Role of the Assisted Insemination Sub-Committee	487
Conclusion	489
Appendix 1: International Approaches to DI	489

Infertility Treatments: *In Vitro* Fertilization**497**

The Views of Canadians	501
The Proliferation of IVF	502
How IVF Services Are Provided	502
Risks Associated with IVF	503
How IVF Is Paid For	504
Access to IVF	506
Decision Making About IVF	506
Origins and Development	507
IVF Procedures	511
The Effectiveness of IVF	511
The Natural Force of Pregnancy	515
The Age of the Female Partner	516
Behavioural and Environmental Factors	517
Effectiveness by Infertility Diagnosis	517
Relative Cost-Effectiveness	522
Cost-Effectiveness of IVF Compared to Tubal Surgery	524
Risks of IVF	527
Multiple Pregnancies	527
Drug Risks	530
Procedural Risks	531
Psychosocial Effects of Treatment	532
Long-Term Outcomes	533
Issues in Current IVF Practice in Canada	534
Clinic Practices	536
"Success" Rates	538
Measuring Health Outcomes	544
Clinic Staff	544
Patient Information, Consent, and Counselling	545
Access to Treatment	551
Referring Physicians	555
Priorities for IVF Research	556
Health Insurance Coverage	560
Criteria for Coverage	560
Dangers of a Two-Tier System	561

Recommendations	564
Licensing Requirements for Assisted Conception Services	566
Conditions of Licence Applicable to Assisted Conception Services	568
Calculation of Clinic Success Rates	571
Non-Commercialization of Assisted Conception Services	572
Reporting and Record Keeping	572
Licence Renewal and Revocation of Licences	573
The Role of the Assisted Conception Sub-Committee	573
Conclusion	576

21 **Handling of Eggs and Embryos** **581**

The Views of Canadians	582
Egg Donation	585
Anonymous Egg Donation by Women Undergoing IVF	587
Egg Donation Before Surgical Sterilization	591
"Altruistic" Egg Donation	591
Designated Egg Donation	592
Payment for Egg Donation	593
Potential Use of Eggs from Fetuses	594
Legal Issues	594
Dealing with "Spare" Embryos	595
Embryo Cryopreservation	596
Legal Control and Informed Consent	597
Embryo Donation	599
Recommendations	600
Egg and Embryo Donation	600
Disposition of Unused Eggs and Zygotes	602
Conclusion	603

22 **Embryo Research** **607**

The Views of Canadians	609
Commission Survey	609
Submissions to the Commission	610
The Aims of Embryo Research	611
Treating Infertility	614
Understanding Infertility	616
Inherited Disorders	617
Regulating Fertility	617
Studying Human Development and Its Disorders	617

Future Directions in Embryo Research	618
Technology Transfer Between Animals and Humans	618
Current Uses of Zygotes in Research in Canada	621
Handling and Use of Eggs and Embryos	621
Research by Pharmaceutical Manufacturers and Biotechnology Companies	623
Sources of Zygotes Used in Research	624
<i>In Vitro</i> Creation of Zygotes	624
Uterine Flushing	624
Potential Availability of Zygotes	625
Alternatives to Research on Human Zygotes	625
Regulation of Embryo Research in Canada	626
Legislation	626
Professional Guidelines	628
Regulation of Embryo Research Internationally	630
Issues and Recommendations	630
The Ethical Uses of Human Zygotes in Research	631
Obtaining Zygotes and Informed Consent	639
Use of Zygotes Following Research	641
Funding Embryo Research	641
Commercialization	643
Accountability	644
Licensing Requirements for Research Using Human Zygotes	646
The Role of the Embryo Research Sub-Committee	649
Conclusion	650
Appendix 1: Current Public Policies on Embryo Research in Eight Countries	651

Volume 2



Preconception Arrangements 661

Preconception Arrangements: What They Are	662
Categories of Preconception Arrangements	663
Current Practices	664
Commercial Arrangements	665
Non-Commercial Arrangements	665
Ways of Dealing with Preconception Arrangements	666
Family Law	666
Contract Law	667
Proposals for Change	668
International Experience	668

Views on Preconception Arrangements	669
An Unacceptable Practice: The Arguments Against	
Commercial Preconception Arrangements	670
An Acceptable Practice: The Arguments for Commercial	
Preconception Arrangements	679
Commercial Arrangements Unacceptable,	
Non-Commercial May Be Acceptable	680
The Commission's Assessment	683
Commercial Arrangements	683
Non-Commercial Arrangements	689
Recommendations	689



Commercial Interests and New Reproductive Technologies

695

The Extent of New Reproductive Technology-Related	
Commercial Interests in Canada	699
Commercial Involvement in New Reproductive	
Technology-Related Products	700
Commercial Involvement in New Reproductive	
Technology-Related Services	705
The Appropriate Role and Regulation of Commercial Interests	709
Research Priorities	710
Ethical Review of Research	712
Conflicts of Interest in Particular Situations	714
Testing of Products and Services	714
Marketing of Products and Services	715
Equal Access	716
Public Subsidy of Private Clinics	716
Commodification	718
Technology Transfer from Animals to Humans	718
Patenting	720
Medical Treatments	721
Zygotes, Embryos, and Fetuses	722
Conclusion	724



Prenatal Diagnosis and Genetic Technologies: Introduction and Social Context

729

The Views of Canadians	733
"The Future is Here"	733
Hope for Treatment and Cure	735
The Potential for Discrimination	736
Concerns About Future Developments and Technology	
Transfer from Animals	737

Prenatal Diagnosis for Congenital Anomalies and Genetic Disease	745
The Risk of Congenital Anomalies and Genetic Disease	746
The Role of Prenatal Diagnosis	749
Diagnostic Testing	749
Carrier Screening	751
Prenatal Screening	751
Issues Raised by Prenatal Diagnosis	754
Our Approach to the Study of Prenatal Diagnosis	755
Current Practice of Prenatal Diagnosis in Canada	756
Genetics Centres	756
Referring Practitioners	764
Patients' Perspective	769
The Growth of Prenatal Diagnosis Services in Canada	771
The Views of Canadians	772
Public Hearings and Submissions	773
Commission Surveys of Canadians	776
Aspects of the Use of Prenatal Diagnosis in Canada	777
Counselling, Information, and Support	778
Consent, Choice, and Individual Autonomy	784
Counselling and Informed Choice in the Referral Network	789
Confidentiality	791
Liability	793
Disabilities	796
Termination of Pregnancy	802
Access	805
The Commission's Stance	810
Using Prenatal Diagnosis Technologies Appropriately	811
Assessing New Prenatal Diagnosis Technologies	822
An Accountable, Well-Managed System: The Genetics Centres	830
Licensing Requirements for Prenatal Diagnosis Services	832
An Accountable, Well-Managed System: The Referral Network	839
The Role of the Prenatal Diagnosis and Genetics Sub-Committee	840
Conclusion	843
Appendix 1: Causes and Risks of Congenital Anomalies and Genetic Disease	846

27	Prenatal Diagnosis for Late-Onset Single-Gene Disorders and for Susceptibility Genes	853
	Prenatal Diagnosis for Late-Onset Single-Gene Disorders	856
	Types of Tests	856
	Current Practices in Canada	858
	Issues in the Use of Prenatal Diagnosis for Late-Onset Single-Gene Disorders	862
	Prenatal Diagnosis for Susceptibility Genes	870
	What Does Susceptibility Testing Actually Tell Us?	872
	The Implications of Adult Susceptibility Testing	875
	The Implications of Prenatal Susceptibility Testing	880
	Conclusion	881
28	Sex Selection for Non-Medical Reasons	885
	The Views of Canadians	886
	Public Hearings and Submissions	887
	Parental Preferences Regarding the Sex of Children and the Use of Sex Selection	889
	Prenatal Diagnosis of Fetal Sex and Sex-Selective Abortion	892
	Current Situation	892
	Issues and Recommendations	896
	Disclosure of Fetal Sex After Testing for a Genetic Disease	901
	Sex-Selective Zygote Transfer	906
	Sex-Selective Insemination	908
	Current Practices	908
	Issues and Recommendations	909
	Conclusion	915
29	Gene Therapy and Genetic Alteration	921
	The Views of Canadians	924
	Public Hearings and Submissions	924
	Surveys of Opinion	925
	Somatic Cell Gene Therapy	927
	Potential Uses of Somatic Cell Gene Therapy	927
	Issues Raised by the Use of Somatic Cell Gene Therapy	931
	Regulating Somatic Cell Gene Therapy	933

Germ-Line Genetic Alteration	936
Potential Uses of Germ-Line Genetic Alteration	936
Issues in the Use of Germ-Line Genetic Alteration	938
Regulating Germ-Line Genetic Alteration	942
Non-Therapeutic Genetic Alteration	943
Conclusion	945

30

Judicial Intervention in Pregnancy and Birth 949

Judicial Intervention Defined	951
The Views of Canadians	953
Legal Issues	954
The Ethical View	956
An Approach Based on Support and Care	961
Conclusion and Recommendations	964

31

Uses of Fetal Tissue 967

The Views of Canadians	969
Commission Surveys	969
Submissions to the Commission	970
Uses of Fetal Tissue	973
Potential Usefulness of Fetal Tissue for Transplantation	975
Growth and Differentiation	975
Culture <i>In Vitro</i>	975
Immunogenicity	976
Restoration of Function in Transplant Recipients	976
Future Directions in Fetal Tissue Research and Treatment	977
Information on Uses of Fetal Tissue in Canada	978
Health Care Facilities, Abortion Clinics, and Medical Laboratories in Canada	979
Pharmaceutical Manufacturers and Biotechnology Companies in Canada	981
The Use of Placental Tissue	981
Uses of Fetal Tissue in Other Countries	983
Obtaining Fetal Tissue	985
Current Sources of Tissue	985
Alternative Sources of Fetal Tissue for Transplantation and Other Research	987
Potential Availability of Fetal Tissue	989
Regulations Relevant to Fetal Tissue Use in Canada	990

Issues and Recommendations	994
The Ethical Uses of Fetal Tissue	995
Obtaining Tissue and Informed Consent	996
Commercialization and Patenting	1001
Funding of Fetal Tissue Research	1004
Accountability	1005
Licensing Requirements for the Provision of Human Fetal Tissue to Users	1006
The Role of the Fetal Tissue Sub-Committee	1008
Conclusion	1009
Appendix 1: The Regulation of Fetal Tissue Use in Other Countries	1010
Appendix 2: The First Canadian Research Using Fetal Tissue Transplantation in Human Beings	1012

Part Three: Overview of Recommendations

Recommendations by Area of Responsibility	1021
Federal Government	1022
Criminal Legislation	1022
Establishing the National Reproductive Technologies Commission	1023
National Council on Bioethics in Human Research	1039
Provincial/Territorial Governments	1040
Health Care Professions	1043
Patients and Other Affected Groups	1047
Commercial Interests	1047
Employers	1048
School Boards	1048
Conclusion	1049

Part Four: Annex, Glossary, and Appendices



Annex: Suzanne Rozell Scorsone

Six Dissenting Opinions	1053
Detailed Reasoning	1067



Glossary

1147



Appendices

A. Mandate	1175
B. Participants in Public Hearings, 1990	1177
C. Participants in Symposia, Colloquia, and Other Commission Activities	1197
D. Written Submissions and Opinions	1229
E. Research Studies	1253
F. Staff of the Commission	1273

Tables

Table 9.1.	Classification of Couples Who Had Been Cohabiting for At Least One Year	187
Table 9.2.	Prevalence of Infertility Among Canadian Couples: Results of Primary Surveys	188
Table 10.1.	History of Previous Sexually Transmitted Disease	202
Table 10.2.	Rates of Gonorrhoea in Canada by Age and Sex	204
Table 10.3.	Reported Cases and Rates of Chlamydial Infection by Age and Sex, Canada, 1989-1990	206
Table 10.4.	Pelvic Inflammatory Disease, Age-Specific Rates, by Age Group, Canada, Selected Years, 1972-1988/89	211
Table 11.1.	Probability of Achieving Live Birth Among Smokers and Non-Smokers	237
Table 12.1.	Estimated Risk of Giving Birth to a Child with a Significant Chromosomal Disorder, by Maternal Age	261
Table 14.1.	Percent Distribution of Women 18 to 49 Years of Age Using Contraceptives, by Method of Contraception and Age Group, Canada, 1984	324
Table 14.2.	Percentage of Cohabiting Couples Who Were Contraceptively Sterilized (Either Tubal Ligation or Vasectomy) in 1991-92	325
Table 19.1.	Screening of Potential Sperm Donors in 1991	450
Table 20.1.	Effectiveness of IVF for Various Infertility Diagnoses	519
Table 20.2.	Average Costs (in Canadian Dollars) per Patient (Six Months' Observation) — 1990	523
Table 20.3.	Services Offered at 16 IVF Programs, 1991	537
Table 20.4.	Different Success Rate Definitions in Current Use in Canada	540
Table 20.5.	Possible or Probable Reasons Clinics Would Refuse Patients for IVF Treatment, 1991	552
Table 20.6.	Source of Referral to Clinic (Sample Size 750 IVF Patients)	555

Table 26.1.	The Causes of Congenital Anomalies	748
Table 26.2.	The Incidence of Genetic Diseases (Onset by Age 25)	748
Table 26.3.	The Incidence of Congenital Anomalies	749
Table 26.4.	Reasons for Referral to Genetics Centres for Prenatal Diagnosis	758
Table 26.5.	Amniocentesis, CVS, and Targeted Ultrasound Performed at Genetics Centres in Canada (1990)	759
Table 26.6.	Referral Rates by Province (1990)	760
Table 26.7.	Referral Rates for Advanced Maternal Age by Province (1990)	761
Table 26.8.	Practitioners Involved in PND at Genetics Centres	763
Table 26.9.	Type of Training of Genetics Associates	764
Table 26.10.	Number of PND Practitioners Outside Genetics Centres (1990)	765
Table 26.11.	Source of Referrals to Genetics Centres (1990)	766
Table 26.12.	Pregnancy Termination After Diagnosis of Fetal Disorder	803
Table 26.13.	Geographical Distribution of Genetics Centres in Canada	806
Table 26.14.	Willingness of Canadians to Use Prenatal Diagnosis	809
Table 26.15.	Number of Obstetrical Ultrasound Procedures	816
Table 31.1.	Permissibility of Using Fetal Tissue	970

Figures

Figure 7.1.	Summary of Fertilization	151
Figure 7.2.	Prenatal Loss in Human Beings	154
Figure 7.3.	Preimplantation Development	156
Figure 7.4.	Process of Implantation	157
Figure 9.1.	Cumulative Conception Rates Among Fertile Couples	184
Figure 10.1.	Gonorrhoea: Annual Incidence per 100 000, Canada, 1940-1991	203
Figure 11.1.	Age-Adjusted Smoking Rates for Population Aged 15 and Over, by Sex, Canada, 1966-1991	242
Figure 12.1.	Age-Specific Fertility Rates, Canada, 1921-1990	253
Figure 12.2.	Percentage Distribution of Live Births by Age of Mother, 1981 and 1991	254
Figure 12.3.	Fertility Rates in Natural Populations	258
Figure 12.4.	Relative Fertility Rates in Natural Populations	259
Figure 16.1.	Domestic Adoptions: Number of Children and Number of Infants Adopted in Canada, 1981-1990	362
Figure 16.2.	Public and Private Domestic Adoptions as a Percentage of All Domestic Adoptions	363
Figure 16.3.	Public and Private Infant Adoptions as a Percentage of All Infant Domestic Adoptions	364
Figure 19.1.	Location of AI Programs in Canada, 1991	436
Figure 19.2.	Outline of Proposed AI System in Canada	473

Figure 20.1.	One IVF Cycle	512
Figure 22.1.	Stages from Fertilization to Birth	612
Figure 26.1.	Relationship Between Congenital Anomalies and Genetic Disease	747